Lv3
236 积分 2026-02-07 加入
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH
14分钟前
已完结
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
1小时前
已完结
Scientific white paper on concentration-QTc modeling
7天前
已完结
Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1
7天前
已完结
Cross talk between angiotensin-(1-7)/Mas axis and sirtuins in adipose tissue and metabolism of high-fat feed mice
18天前
已完结
The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger
28天前
已完结
The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger
28天前
已完结
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
1个月前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
1个月前
已完结
Review Article: An Update on Non-Invasive Tests for Steatotic Liver Disease - Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies
1个月前
已完结
皖公网安备34019202002308
